Tyrphostins, inhibitors of protein tyrosine kinase, in restenosis

Advanced Drug Delivery Reviews

Volumn 24, Issue 1, 1997, Pages 53-62

  Golomb, Gershon ^a   Fishbein, Ilia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

controlled release; Drug implants; implantable drug delivery system; PDGF; protein tyrosine kinase; restenosis; tyrphostin

Indexed keywords

BLOOD VESSELS; CARDIOLOGY; CELL CULTURE; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; ENZYME INHIBITION; ENZYMES; IMPLANTS (SURGICAL); MUSCLE;

DRUG IMPLANTS; IMPLANTABLE DELIVERY SYSTEM; PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY; PROTEIN TYROSINE KINASE; RESTENOSIS; SMOOTH MUSCLE CELLS; TYRPHOSTINS;

DRUG PRODUCTS;

3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 808; ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; ANGIOTENSIN; DRUG CARRIER; MACROGOL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTERY OCCLUSION; AUTOPHOSPHORYLATION; BLOOD VESSEL INJURY; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; HUMAN; IMPLANT; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0031568943     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00482-6     Document Type: Review

References (80)

1. [1] Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362, 801-809.
2. [2] Bornfeldt, K.E., Raines, E.W., Nakano, T., Graves, L.M., Krebs, E.G. and Ross, R. (1994) Insulin-like growth factor-I and platelet-derived growth factor-BB induce direct migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest., 93, 1266-1274.
3. [3] Ross, R., Raines, E.W. and Bowen-Pope, D.F. (1986) The biology of platelet-derived growth factor. Cell 46, 155-169.
4. [4] Adams, P.C., Badimon, J.J., Badimon, L., Chesebro, J.H. and Fuster, V. (1987) Role of platelets in atherogenesis: relevance to coronary arterial restenosis after angioplasty. Cardiovasc. Clin. 18, 49-71.
5. [5] Majesky, M.W., Reidy, M.A., Bowen-Pope, D.F., Hart, C.E., Wilcox, J.N. and Schwartz, S.M. (1990) PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell Biol. 111, 2149-2158.
6. [6] Ferns, G.A.A., Raines, E.W., Sprugel, K.H., Motani, A.S., Reidy, M.A. and Ross, R. (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253, 1129-1132.
7. [7] Jawien, A., Bowen-Pope, D.F., Linder, V., Schwartz, S.M. and Clowes, A.W. (1992) Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest., 507-511.
8. [8] Kraiss, L.W., Raines, E.W., Wilcox, J.N., Seifert, R.A., Barrett, T.B., Kirkman, T.R., Hart, C.E., Bowen-Pope, D.F., Ross, R. and Clowes, A.W. (1993) Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly. J. Clin. Invest. 92, 338-348.
9. [9] Weinstein, R. and Wenc, K. (1986) Growth factor responses of human arterial endothelial cells in vitro. Cell Dev. Biol. 22, 549-556.
10. [10] Lindner, V., Reidy, M.A. and Fingerle, J. (1989) Regrowth of arterial endothelium. Denudation with minimal trauma leads to complete endothelial cell regrowth. Lab. Invest. 61, 556-563.
11. [11] Lindner, V. and Reidy, M.A. (1991) Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88, 3739-3743.
12. [12] Badesch, D.B., Lee, P.D., Parks, W.C. and Stenmark, K.R. (1989) Insulin-like growth factor 1 stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells. Biochem. Biophys. Res. Commun. 160, 382-387.
13. [13] Booth, B.A., Bar, R.S., Boes, M., Dake, B.L., Bayne, M. and Cascieri, M. (1990) Intrinsic bioactivity of insulin-like growth factor-binding proteins from vascular endothelial cells. Endocrinology 127, 2630-2638.
14. [14] Ferns, G.A., Motani, A.S. and Anggard, E.E. (1991) The insulin-like growth factors: their putative role in atherogenesis. Artery 18, 197-225.
15. [15] Bjorkerud, S. (1991) Effects of transforming growth factor β 1 on human arterial smooth muscle cells in vitro. Arterioscler. Thromb. 11, 892-902.
16. [16] Cai, J.P., Falanga, V. and Chin, Y.-H. (1991) Transforming growth factor-β regulates the adhesive interactions between mononuclear cells and microvascular endothelium. J. Invest. Dermatol. 97, 169-174.
17. [17] Gay, C.G. and Winkles, J.A. (1991) Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc. Natl. Acad. Sci. USA 88, 296-300.
18. [18] Grosenbaugh, D.A., Amoss, M.S., Hood, D.M., Morgan, S.J. and Williams, J.D. (1988) Epidermal growth factor-mediated effects on equine vascular smooth muscle cells. Am. J. Physiol. 255, C477-451.
19. [19] Casscells, W. (1991) Smooth muscle cell growth factors. Prog. Growth Factor Res. 3, 177-206.
20. [20] Newby, A.C. and George, S.J. (1993) Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc. Res., 1173-1183.
21. [21] Casscells, W., Lappi, D.A. and Baird, A. (1993) Molecular atherectomy for restenosis. Trends Cardiovasc. Med. 3, 235-243.
22. [22] Deuel, T. (1987) Polypeptide growth factors: roles in normal and abnormal cell growth. Annu. Rev. Cell Biol. 3, 443-492.
23. [23] Yarden, Y. and Ullrich, A. (1988) Growth factor receptor tyrosine kinases. Annu. Rev. Bioehem. 57, 443-478.
24. [24] Ullrich, A. and Schlessinger, J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 203-212.
25. [25] Levitzki, A. (1992) Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6, 3275-3282.
26. [26] Levitzki, A. and Gazit, A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788.
27. [27] Shimokado, K., Yokota, T., Kosaka, C., Zen, K., Sasaguri, T., Masuda, J. and Ogata, J. (1995) Protein tyrosine kinase inhibitors inhibit both proliferation and chemotaxis of vascular smooth muscle cells. Ann. NY Acad. Sci. 748, 171-175.
28. [28] Bilder, G.E., Krawiec, J.A., McVety, K., Gazit, A., Gilon, C., Lyall, R., Zilberstein, A., Levitzki, A., Perrone, M.H. and Schreiber, A.B. (1991) Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260, C721-C730.
29. [29] Banai, S., Schneider, A., Gertz, S.D., Colomb, G., Levitzki, A. and Wolf, Y. (1996) Effect of Selective PDGF-Receptor Versus Non-Selective Protein Tyrosine Kinase Blockers on Aortic Smooth Musscle Cells (SMC's) and Endothelial Cells Proliferation [abstract]. J. Am. Coll. Cardiol., in press.
30. [30] Muller, D.W.M., Ellis, S.G. and Topol, E.J. (1992) Experimental models of coronary artery restenosis. J. Am. Coll. Cardiol. 19, 418-432.
31. [31] Muller, D.W.M., Colomb, G., Gordon, D. and Levy, R.J. (1994) Site-specific dexamethasone delivery for the prevention of neointimalthickening after vascular stent implantation. Coron. Artery Dis. 5, 435-442.
32. [32] Edelman, E.R. and Karnovsky, M.J. (1994) Contrasting effects of the intermittent and continues administration of heparin in experimental restenosis. Circulation 89, 770-776.
33. [33] Shimokado, K., Yokota, T., Umezawa, K., Sasaguri, T. and Ogata, J. (1994) Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Atherioscler. Thromb. 14, 973-981.
34. [34] Bilder, G.E., Kasiewski, C.J., Walczak, E.M. and Perrone, M.H. (1993) PDGF-receptor protein tyrosine kinase activity in carotid artery is enhanced by injury and inhibited in vivo by tyrphostin RG 13291. Drug Dev. Res. 29, 158-166.
35. [35] Ito, A., Shimokawa, H., Kadokami, T., Fukumoto, Y., Owada, M.K., Shiraishi, T., Nakaike, R., Takayanagi, T., Egashira, K. and Takeshita, A. (1995) Tyrosine kinase inhibitors supress coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-β1 in pigs in vivo. J. Clin. Invest. 96, 1288-1294.
36. [36] Fukumoto, Y., Shimokawa, H., Kozai, T. and Takeshita, A. (1995) A selective tyrosine kinase inhibitor, ST 638, markedly reduces the intimal thickening of the coronary artery after balloon injury in pigs. Circulation 92, 1-572.
37. [37] Clowes, A.W., Reidy, M.A. and Clowes, M.M. (1983) Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab. Invest. 49, 327-333.
38. [38] Okada, T., Bark, D.H. and Mayberg, M.R. (1989) Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery 25, 892-898.
39. [39] Edelman, E.R., Adams, D.H. and Karnovsky, M.J. (1990) Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. USA 87, 3773-3777.
40. [40] Simons, M., Edelman, E.R., DeKeyser, J.-L., Langer, R. and Rosenberg, R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
41. [41] Villa, A.E., Guzman, L.A., Chen, W., Golomb, G., Levy, R.J. and Topol, E.J. (1994) Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J. Clin. Invest. 93, 1243-1249.
42. [42] Edelman, E.R., Nugent, M.A., Smith, L.T. and Karnovsky, M.J. (1992) Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proiferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89, 465-473.
43. [43] Ramdas, L., McMurray, J.S. and Budde, R.J.A. (1994) The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability. Cancer Res. 54, 867-869.
44. [44] Golomb, G., Fishbein, I., Banai, S., Mishaly, D., Moscovitz, D., Gertz, S.D., Gazit, A., Poradosu, E. and Levitzki, A. (1996) Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 125, 171-182.
45. [45] Ron, E., Turek, T., Mathiowitz, E., Chasin, M., Hageman, M. and Langer, R. (1993) Controlled release of polypeptides from polyanhydrides. Proc. Natl. Acad. Sci. USA 90, 4176-4180.
46. [46] Castantino, H.R., Langer, R. and Klibanov, A.M. (1994) Moisture-induced aggregation of lyophilized insulin. Phram. Res. 11, 21-29.
47. [47] Roseman, T.J. and Higuchi, W.J. (1970) Release of medroxyprogesterone acetate from a silicone polymer. J. Pharm. Sci. 59, 353-357.
48. [48] Miller, E.S., Peppas, N.A. and Winslow, D.N. (1983) Morphological changes of ethylene/vinyl acetate-based controlled delivery systems during release of water soluble solutes. J. Memb. Sci. 14, 79-92.
49. [49] Golomb, G., Langer, R., Schoen, F.J., Smith, S.M., Choi, Y. and Levy, R.J. (1986) Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. J. Control. Release 4, 181-194.
50. [50] Golomb, G., Dixon, M., Smith, M.S., Schoen, F.J. and Levy, R.J. (1987) Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic hear: valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. J. Pharm. Sci. 76, 271-276.
51. [51] Wolbring, G., Hollenberg, M.D. and Schnetkamp, P.P.M. (1994) Inhibition of GTP-utilizing enzymes by tyrphostins. J. Biol. Chem. 269, 22470-22472.
52. [52] Munoz, E., Zubiaga, A., Huang, C. and Huber, B.T. (1992) Interleukin-1 induces protein tyrosine phosphorylation in T cells. Eur. J. Immunol. 22, 1391-1396.
53. [53] Padeh, S., Levitzki, A., Gazit, A., Mills, G.B. and Roifman, C.M. (1991) Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation. J. Clin. Invest. 87, 1114-1118.
54. [54] Melamed, L. Downey, G.P. and Roifman, C. (1991) Tyrosine phosphorylation is essential tor microfilament assembly in B lymphocytes. Biochem. Biophys. Res. Commun. 176, 1424-1429.
55. [55] Ferns, G.A.A., Reidy, M.A. and Ross, R. (1991) Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absense of functional T-lymphocytes. Am. J. Pathol. 138, 1045-1057.
56. [56] Burger, A.M., Kaur, G., Alley, M.C., Supko, J.G., Malespeis, L., Grever, M.R. and Sausville, E.A. (1995) Tyrphostin AG-17. [(3,5-Di-tert-butyl-4-hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res. 55, 2794-2799.
57. [57] Gorski, D.H. and Walsh, K. (1995) Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Cardiovasc. Res. 30, 585-592.
58. [58] Abedi, H. and Zachary, I. (1995) Signalling mechanisms in the regulation of vascular smooth muscle cell migration. Cardiovasc. Res. 30, 544-556.
59. [59] Choi, E.T., Engel, L., Callow, A.D., Sun, S., Trachtenberg, J., Santoro, S. and Ryan, U.S. (1994) Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. 19, 125-134.
60. [60] Matsuno, H., Stassen, J.M., Vermylen, J. and Deckmyn, H. (1994) Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 90, 2203-2206.
61. [61] Kraus, M. and Wolf, B. (1994) Ising model for cooperative processing of extracellular information by protein-tyrosine kinasess and cell adhesion molecules. Biosystems 33, 89-98.
62. [62] Schlaepfer, D.D., Hanks, S.K., Hunter, T. and van der Geer, P. (1994) Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 372, 786-791.
63. [63] Hosoi, M., Takasaki, I., Pavlova-Rezakova, A., Himeno, H., Chobanian, A.V. and Brecher, P. (1993) Selective induction of an embryonic fibronectin isoform in the rat aorta in vitro. Circ. Res. 73, 689-695.
64. [64] Huang, M.-M., Lipfert, L., Cunningham, M., Brugge, J.S., Ginsberg, M.H. and Shattil, S.J. (1993) Adhesive ligand binding to integrin αIIβ33 stimulates tyrosine phosphorylation of novel protein substrates prior to phosphorylation of pp125FAK. J. Cell Biol. 122, 473-478.
65. [65] Guinebault, C., Payrastre, B. and Sultan, C. (1993) Tyrosine kinases and phosphoinositide metabolism in thrombin-stimulated human platelets. Biochem. J. 292, 851-856.
66. [66] Asahi, M. Yanagi, S. and Ohta, S. (1992) Thrombin-induced human platelet aggregation is inhibited by protein-tyrosine kinase inhibitors. ST638 and genistein. FEBS Lett. 309, 10-14.
67. [67] Salari, H., Duronio, V. and Howard, S.L. (1990) Erbstatin blocks platelet activating factor-induced protein-tyrosine phosphorylation, polyphosphoinositide hydrolysis, protein kinase C activation, serotonin secretion and aggregation of rabbit platelets. FEBS Lett. 263, 104-108.
68. [68] Jang, Y., Lincoff, A.M., Plow, E.F. and Topol, E.J. (1994) Cell adhesion molecules in coronary artery disease. J. Am. Coll. Cardiol. 24, 1591-1601.
69. [69] Weber, C., Negrescu, E., Erl, W., Siess, W. and Weber, P.C. (1995) Tumor necrosis factor stimulated induction of endothelial cell adhesion molecule requires tyrosine phosphorylation. Atherosclerosis 115 (Suppl.). S11.
70. [70] Rakugi, H., Jacob, H.J., Krieger, J.E., Ingelfinger, J.R. and Pratt, R.E. (1993) Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 87, 283-290.
71. [71] Wong, P.C., Price, W.A., Chiu, A.T., Duncia, J.V., Carini, D.J., Wexler, R.R. and Johnson, A.L. (1991) In vivo pharmacology of DuP 753. Am. J. Hypertens. 4, 288S-298S.
72. [72] Murphy, T.J., Alexander, R.W., Griendling, K.K., Runge, M.S. and Bernstein, K.E. (1991) Isolation of cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351, 233-236.
73. [73] Marrero, M.B., Schiefrer, B., Paxton, W.G., Duff, J.L., Berk, B.C. and Bernstein, K.E. (1995) The role of tyrosine phosphorylation in angiotensin II-mediated intracellular signalling. Cardiovasc. Res. 30, 530-536.
74. c Src in vascular smooth muscle cells. Circ. Res. 77, 1053-1059.
75. [75] Linseman, D.A., Benjamin, C.W. and Jones, D.A. (1995) Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J. Biol. Chem. 270, 12563-12568.
76. [76] Simonson, M.S. and Herman, W.H. (1993) Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signalling by endothelin-1. J. Biol. Chem. 268, 9347-9357.
77. [77] Weiss, R.H. and Nuccitelli, R. (1992) Inhibition of tyrosine phosphorylation prevents thrombin induced mitogenesis but not intracellular free calcium release, in vascular smooth muscle cells. J. Biol. Chem. 267, 5608-5613.
78. [78] Bennett, M.R., Anglin, S., McEwan, J.R., Jagoe, R., Newby, A.C. and Ivan, G.I. (1994) Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by C-myc antisense oligonucleotides. J. Clin. Invest. 93, 820-828.
79. [79] Simons, M., Edelman, E.R. and Rosenberg, R.D. (1994) Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93, 2351-2356.
80. [80] Epstein, S.E., Speir, E. and Finkel, T. (1993) Do antisense approaches to the problem of restenosis make sense? Circulation 88, 1351-1353.